Biblio Discovery — Demo Discovery Service

21 hasil untuk "Justin Ritz"

Menampilkan 1–20 · 0,51 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Evolutionary evidence for alternative structure in RNA sequence co-variation.

    Justin Ritz; Joshua S Martin; Alain Laederach

    PLoS Computational Biology, Vol. 9 No. 7 · 2013 · Inggris · DOAJ Scopus

    Sequence conservation and co-variation of base pairs are hallmarks of structured RNAs. For certain RNAs (e.g. riboswitches), a single sequence must adopt at least two alternative secondary structures to effectively regulate the message. If alternative secondary structures are important to the…

    Juga tersedia di: PLOS

  2. Artikel Jurnal Teks lengkap

    Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials

    McNeil Ngongondo; Justin Ritz; Michael D. Hughes dkk.

    PLOS Global Public Health, Vol. 4 No. 1 · 2024 · Inggris · DOAJ Scopus

    Tenofovir disoproxil fumarate (TDF), a potent and commonly used antiretroviral drug, is associated with renal tubular dysfunction and renal adverse events. We evaluated the frequency of, time to, and baseline risk factors for discontinuing TDF from initial antiretroviral therapy (ART) regimens…

    Juga tersedia di: DOAJ, PLOS

  3. Artikel Jurnal Teks lengkap

    Structure-Function Model for Kissing Loop Interactions That Initiate Dimerization of Ty1 RNA

    Eric R. Gamache; Jung H. Doh; Justin Ritz dkk.

    Viruses, Vol. 9 No. 5 · 2017 · Inggris · DOAJ Scopus

    The genomic RNA of the retrotransposon Ty1 is packaged as a dimer into virus-like particles. The 5′ terminus of Ty1 RNA harbors cis-acting sequences required for translation initiation, packaging and initiation of reverse transcription (TIPIRT). To identify RNA motifs involved in dimerization and…

  4. Artikel Jurnal

    The lncRNA SLNCR1 Mediates Melanoma Invasion through a Conserved SRA1-like Region

    Karyn Schmidt; Cailin E. Joyce; Frank Buquicchio dkk.

    Cell Reports, Vol. 15 No. 9 · 2016 · Inggris · DOAJ Scopus

    Long non-coding RNAs (lncRNAs) have been implicated in numerous physiological processes and diseases, most notably cancers. However, little is known about the mechanism of many functional lncRNAs. We identified an abundantly expressed lncRNA associated with decreased melanoma patient survival…

  5. Artikel Jurnal

    The lncRNA SLNCR Recruits the Androgen Receptor to EGR1-Bound Genes in Melanoma and Inhibits Expression of Tumor Suppressor p21

    Karyn Schmidt; Johanna S. Carroll; Elaine Yee dkk.

    Cell Reports, Vol. 27 No. 8 · 2019 · Inggris · DOAJ Scopus

    Summary: Melanoma is the deadliest form of skin cancer, affecting men more frequently and severely than women. Although recent studies suggest that differences in activity of the androgen receptor (AR) underlie the observed sex bias, little is known about AR activity in melanoma. Here we show that…

  6. Artikel Jurnal

    Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance

    Robert A. Salata; Beatriz Grinsztejn; Justin Ritz dkk.

    AIDS Research and Therapy, Vol. 20 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Background Treatment management after repeated failure of antiretroviral therapy (ART) is difficult due to resistance and adherence challenges. For people who have failed non-nucleoside reverse transcriptase inhibitor-(NNRTI-) and protease inhibitor-(PI-) based regimens with no or limited…

  7. Artikel Jurnal

    Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

    Katya Corado; Kara Chew; Mark Giganti dkk.

    Pathogens and Immunity, Vol. 9 No. 1 · 2024 · Inggris · DOAJ Scopus

    Background: Outpatient COVID-19 monoclonal antibody (mAb) treatment via subcutaneous delivery, if effective, overcomes the logistical burdens of intravenous administration. Methods: ACTIV-2/A5401 was a randomized, masked placebo-controlled platform trial where participants with COVID-19 at low risk…

  8. Artikel Jurnal

    Association of long COVID with health-related quality-of-life outcomes

    Malini M. Gandhi; Carlee Moser; Judith S. Currier dkk.

    Scientific Reports, Vol. 16 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract The association of long COVID with health-related quality-of-life (HrQOL) has not been well-characterized. Participants who received blinded placebo in the ACTIV-2/A5401 outpatient COVID-19 treatment trial were included in an analysis of the association of long COVID with HrQOL (both…

  9. Artikel Jurnal

    Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial

    Robert Gross, MD MSCE; Justin Ritz, MS; Michael D Hughes, ProfPhD dkk.

    The Lancet: Digital Health, Vol. 1 No. 1 · 2019 · Inggris · DOAJ Scopus

    Summary: Background: Antiretroviral therapy (ART) non-adherence causes HIV treatment failure. Past behaviour might predict future behaviour; failing second-line ART could indicate ongoing risk for subsequent non-adherence. We aimed to find out whether a two-way mobile phone-based communication…

  10. Artikel Jurnal

    Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

    Rachel A. Bender Ignacio; Kara W. Chew; Carlee Moser dkk.

    iScience, Vol. 28 No. 3 · 2025 · Inggris · DOAJ Scopus

    Summary: Monoclonal antibodies have potential as rapidly developable agents for treatment and prevention of emerging viruses. The ACTIV-2 trial randomized persons with mild-moderate COVID-19 to the monoclonal antibody combination tixagevimab/cilgavimab via intramuscular injection (600 mg IM) or…

  11. Artikel Jurnal

    Impact of Sex on Viral Shedding and Symptom Severity During Acute COVID-19

    Evelyn Kung; Rinki Deo; Manish C. Choudhary dkk.

    Pathogens and Immunity, Vol. 11 No. 1 · 2026 · Inggris · DOAJ Scopus

    Background: To evaluate the impact of sex on acute SARS-CoV-2 infection, 668 participants from the ACTIV-2/A5401 study were followed over a 28-day period. Methods: A primary analysis was performed on 469 participants with quantifiable viral loads at baseline. Results: Male and female participants…

  12. Artikel Jurnal

    Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2

    Sydney I. Ramirez; Paul G. Lopez; Farhoud Faraji dkk.

    JCI Insight, Vol. 9 No. 24 · 2024 · Inggris · DOAJ Scopus

    T cells are involved in protective immunity against numerous viral infections. Data regarding functional roles of human T cells in SARS-CoV-2 (SARS2) viral clearance in primary COVID-19 are limited. To address this knowledge gap, we assessed samples for associations between SARS2 upper respiratory…

  13. Artikel Jurnal

    Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses

    Sydney I. Ramirez; Alba Grifoni; Daniela Weiskopf dkk.

    JCI Insight, Vol. 7 No. 24 · 2022 · Inggris · DOAJ Scopus

    Despite the widespread use of SARS-CoV-2–specific monoclonal antibody (mAb) therapy for the treatment of acute COVID-19, the impact of this therapy on the development of SARS-CoV-2–specific T cell responses has been unknown, resulting in uncertainty as to whether anti–SARS-CoV-2 mAb administration…

  14. Artikel Jurnal

    Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

    Kara W. Chew; Carlee Moser; Eric S. Daar dkk.

    Nature Communications, Vol. 13 No. 1 · 2022 · Inggris · DOAJ Scopus

    In April 2021, Eli Lilly voluntarily asked the FDA to revoke the Emergency Use Authorization for the monoclonal antibody bamlanivimab due to reduced susceptibility in vitro to SARS-CoV-2 variants, not for safety. In this work, authors carry out a placebo-controlled phase 2 evaluation of…

  15. Artikel Jurnal

    Sirolimus reduces T cell cycling, immune checkpoint marker expression, and HIV-1 DNA in people with HIV

    Timothy J. Henrich; Ronald J. Bosch; Catherine Godfrey dkk.

    Cell Reports Medicine, Vol. 5 No. 10 · 2024 · Inggris · DOAJ Scopus

    Summary: Key HIV cure strategies involve reversing immune dysfunction and limiting the proliferation of infected T cells. We evaluate the safety of sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in people with HIV (PWH) and study the impact of sirolimus on HIV-1 reservoir size and…

  16. Artikel Jurnal

    Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialResearch in context

    Prasanna Jagannathan; Kara W. Chew; Mark J. Giganti dkk.

    EClinicalMedicine, Vol. 65 · 2023 · Inggris · DOAJ Scopus

    Summary: Background: With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of novel therapeutics to prevent progression to severe COVID-19 remains a critical need. Methods: Safety, clinical and antiviral…